William Blair analyst Matt Phipps has maintained their bullish stance on JSPR stock, giving a Buy rating today.
Matt Phipps has given his Buy rating due to a combination of factors including the promising data from Jasper Therapeutics’ BEACON study. The recent updates from the Phase I/II study of briquilimab in patients with chronic spontaneous urticaria have shown positive trends, with improved responses at the 180 mg dose level and consistent safety and efficacy data. The new sub-analysis supports the dose-responsive efficacy of briquilimab, and the safety profile remains favorable with manageable side effects.
Furthermore, Jasper’s management has outlined significant upcoming milestones, including midyear data updates involving approximately 70 new patients, which will aid in dose selection for further pivotal development. These developments, alongside the company’s strategic plans for an adaptive Phase IIb study in the latter half of the year, present potential catalysts for the stock. Despite the need for additional capital, the anticipated study updates could enhance briquilimab’s competitive profile, supporting the Buy rating.
According to TipRanks, Phipps is an analyst with an average return of -10.4% and a 36.29% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Kezar Life Sciences, Keros Therapeutics, and Jasper Therapeutics.